Alexander disease

Journal of Neuroscience

Volumn 32, Issue 15, 2012, Pages 5017-5023

  Messing, Albee ^a   Brenner, Michael ^b   Feany, Mel B ^c   Nedergaard, Maiken ^d   Goldman, James E ^e  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Alabama at Birmingham   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CRYSTALLIN; BETA CRYSTALLIN; CEFTRIAXONE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ALEXANDER DISEASE; ARTICLE; ASTROCYTE; ATROPHY; AUTOPHAGY; BRAIN DYSFUNCTION; CELL LOSS; DEMYELINATION; DEVELOPMENTAL DISORDER; GAIN OF FUNCTION MUTATION; GRAY MATTER; HUMAN; LEUKODYSTROPHY; NONHUMAN; OLIGODENDROGLIA; ONSET AGE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEIZURE; SPASTICITY; WHITE MATTER;

AGE OF ONSET; ALEXANDER DISEASE; ANIMALS; ASTROCYTES; BRAIN; DISEASE MODELS, ANIMAL; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MODELS, NEUROLOGICAL; NEURAL PATHWAYS;

EID: 84859538305     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5384-11.2012     Document Type: Article

References (57)

1. Alexander WS (1949) Progressive fibrinoid degeneration of fibrillary astrocytes associated with mental retardation in a hydrocephalic infant. Brain 72:373-381.
2. Barkovich AJ, Messing A (2006) Alexander disease: not just a leukodystrophy anymore. Neurology 66:468-469.
3. Blattner R, Von Moers A, Leegwater PA, Hanefeld FA, Van Der Knaap MS, Köhler W (2003) Clinical and genetic heterogeneity in megalencephalic leukoencephalopathy with subcortical cysts (MLC). Neuropediatrics 34:215-218.
4. Brady JP, Garland DL, Green DE, Tamm ER, Giblin FJ, Wawrousek EF (2001) αB-crystallin in lens development and muscle integrity: a gene knockout approach. Invest Ophthalmol Vis Sci 42:2924-2934.
5. Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Goldman JE, Messing A (2001) Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 27:117-120.
6. Brenner M, Goldman JE, Quinlan RA, Messing A (2009) Alexander disease: a genetic disorder of astrocytes. In: Astrocytes in (patho)physiology of the nervous system (Parpura V, Haydon PG, eds), pp 591-648. New York: Springer.
7. Buffo A, Rolando C, Ceruti S (2010) Astrocytes in the damaged brain: molecular and cellular insights into their reactive response and healing potential. Biochem Pharmacol 79:77-89.
8. Bugiani M, Boor I, van Kollenburg B, Postma N, Polder E, van Berkel C, van Kesteren RE, Windrem MS, Hol EM, Scheper GC, Goldman SA, van der Knaap MS (2011) Defective glial maturation in vanishing white matter disease. J Neuropathol Exp Neurol 70:69-82.
9. Chen YS, Lim SC, Chen MH, Quinlan RA, Perng MD (2011) Alexander disease causing mutations in the C-terminal domain of GFAP are deleterious both to assembly and network formation with the potential to both activate caspase 3 and decrease cell viability. Exp Cell Res 317:2252-2266.
10. Chin SS, Goldman JE (1996) Glial inclusions in CNS degenerative diseases. J Neuropathol Exp Neurol 55:499-508.
11. Cho W, Messing A (2009) Properties of astrocytes cultured from GFAP over-expressing and GFAP mutant mice. Exp Cell Res 315:1260-1272.
12. Cho W, Brenner M, Peters N, Messing A (2010) Drug screening to identify suppressors of GFAP expression. Hum Mol Genet 19:3169-3178.
13. Del Bigio MR, Chudley AE, Sarnat HB, Campbell C, Goobie S, Chodirker BN, Selcen D (2011) Infantile muscular dystrophy in Canadian aboriginals is an αB-crystallinopathy. Ann Neurol 69:866-871.
14. Deng W, Yue Q, Rosenberg PA, Volpe JJ, Jensen FE (2006) Oligodendrocyte excitotoxicity determined by local glutamate accumulation and mitochondrial function. J Neurochem 98:213-222.
15. Eng LF, Lee YL, Kwan H, Brenner M, Messing A (1998) Astrocytes cultured from transgenic mice carrying the added human glial fibrillary acidic protein gene contain Rosenthal fibers. J Neurosci Res 53:353-360.
16. Friede RL (1964) Alexander's disease. Arch Neurol 11:414-422.
17. Fuchs E, Cleveland DW (1998) Astructural scaffolding of intermediate filaments in health and disease. Science 279:514-519.
18. Hagemann TL, Gaeta SA, Smith MA, Johnson DA, Johnson JA, Messing A (2005) Gene expression analysis in mice with elevated glial fibrillary acidic protein and Rosenthal fibers reveals a stress response followed by glial activation and neuronal dysfunction. Hum Mol Genet 14:2443-2458.
19. Hagemann TL, Connor JX, Messing A (2006) Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response. J Neurosci 26:11162-11173.
20. Hagemann TL, Boelens WC, Wawrousek EF, Messing A (2009) Suppression of GFAP toxicity by αB-crystallin in mouse models of Alexander disease. Hum Mol Genet 18:1190-1199.
21. He T, Stepulak A, Holmström TH, Omary MB, Eriksson JE (2002) The intermediate filament protein keratin 8 is a novel cytoplasmic substrate for c-Jun N-terminal kinase. J Biol Chem 277:10767-10774.
22. Iwaki T, Kume-Iwaki A, Liem RK, Goldman JE (1989) αB-Crystallin is expressed in nonlenticular tissues and accumulates in Alexander's disease brain. Cell 57:71-78.
23. Jany P, Hagemann TL, Messing A (2011) Biomarkers of CNS injury in mouse models of Alexander disease. Soc Neurosci Abstr 37:875.20/13.
24. Li R, Messing A, Goldman JE, Brenner M (2002) GFAP mutations in Alexander disease. Int J Dev Neurosci 20:259-268.
25. Messing A, Head MW, Galles K, Galbreath EJ, Goldman JE, Brenner M (1998) Fatal encephalopathy with astrocyte inclusions inGFAPtransgenic mice. Am J Pathol 152:391-398.
26. Messing A, Daniels CM, Hagemann TL (2010) Strategies for treatment in Alexander disease. Neurotherapeutics 7:507-515.
27. Messing A, Li R, Naidu S, Taylor JP, Silverman L, Flint D, van der Knaap MS, Brenner M (2012) Archetypal and new families with Alexander disease and novel mutations in GFAP. Arch Neurol 69:208-214.
28. Namekawa M, Takiyama Y, Aoki Y, Takayashiki N, Sakoe K, Shimazaki H, Taguchi T, Tanaka Y, Nishizawa M, Saito K, Matsubara Y, Nakano I (2002) Identification of GFAP gene mutation in hereditary adult-onset Alexander's disease. Ann Neurol 52:779-785.
29. Nedergaard M, Ransom B, Goldman SA (2003) New roles for astrocytes: Redefining the functional architecture of the brain. Trends Neurosci 26:523-530.
30. Omary MB (2009) "IF-pathies": a broad spectrum of intermediate filament-associated diseases. J Clin Invest 119:1756-1762.
31. Pareyson D, Fancellu R, Mariotti C, Romano S, Salmaggi A, Carella F, Girotti F, Gattellaro G, Carriero MR, Farina L, Ceccherini I, Savoiardo M (2008) Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. Brain 131:2321-2331.
32. Perng MD, Wen SF, Gibbon T, Middeldorp J, Sluijs J, Hol EM, Quinlan RA (2008) Glial fibrillary acidic protein filaments can tolerate the incorporation of assembly-compromised GFAP-d, but with consequences for filament organization and αB-crystallin association. Mol Biol Cell 19:4521-4533.
33. Prust M, Wang J, Morizono H, Messing A, Brenner M, Gordon E, Hartka T, Sokohl A, Schiffmann R, Gordish-Dressman H, Albin R, Amartino H, Brockman K, Dinopoulos A, Dotti MT, Fain D, Fernandez R, Ferreira J, Fleming J, Gill D, et al (2011) GFAP mutations, age of onset, and clinical sub-types in Alexander disease. Neurology 77:1287-1294.
34. + pumps. J Physiol 522:427-442.
35. Regan MR, Huang YH, Kim YS, Dykes-Hoberg MI, Jin L, Watkins AM, Bergles DE, Rothstein JD (2007) Variations in promoter activity reveal a differential expression and physiology of glutamate transporters by glia in the developing and mature CNS. J Neurosci 27:6607-6619.
36. Rempe DA, Nedergaard M (2010) Targeting glia for treatment of neurological disease. Neurotherapeutics 7:335-337.
37. Rosenthal W (1898) Über eine eigenthümliche, mit syringomyelie complicirte geschwulst des rückenmarks. Bietr Pathol Anat 23:111-143.
38. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB (2005) β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433:73-77.
39. Russo LS Jr, Aron A, Anderson PJ (1976) Alexander's disease: a report and reappraisal. Neurology 26:607-614.
40. Sheldon AL, Robinson MB (2007) The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int 51:333-355.
41. Stumpf E, Masson H, Duquette A, Berthelet F, McNabb J, Lortie A, Lesage J, Montplaisir J, Brais B, Cossette P (2003) Adult Alexander disease with autosomal dominant transmission: a distinct entity caused by mutation in the glial fibrillary acid protein gene. Arch Neurol 60:1307-1312.
42. Su M, Hu H, Lee Y, d'Azzo A, Messing A, Brenner M (2004) Expression specificity of GFAP transgenes. Neurochem Res 29:2075-2093.
43. Tanaka KF, Takebayashi H, Yamazaki Y, Ono K, Naruse M, Iwasato T, Itohara S, Kato H, Ikenaka K (2007) The murine model of Alexander disease: analysis of GFAP aggregate formation and its pathological significance. Glia 55:617-631.
44. Tang G, Xu Z, Goldman JE (2006) Synergistic effects of theSAPK/JNKandthe proteasome pathway on glial fibrillary acidic protein (GFAP) accumulation in Alexander disease. J Biol Chem 281:38634-38643.
45. Tang G, Yue Z, Talloczy Z, Hagemann T, Cho W, Messing A, Sulzer DL, Goldman JE (2008) Autophagy induced by Alexander diseasemutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathways. Hum Mol Genet 17:1540-1555.
46. Tang G, Perng MD, Wilk S, Quinlan R, Goldman JE (2010) Oligomers of mutant glial fibrillary acidic protein (GFAP) inhibit the proteasome system in Alexander disease astrocytes, and the small heat shock protein, αB-crystallin, reverses the inhibition. J Biol Chem 285:10527-10537.
47. Tian R, Gregor M, Wiche G, Goldman JE (2006) Plectin regulates the organization of glial fibrillary acidic protein in Alexander disease. Am J Pathol 168:888-897.
48. Tian R, Wu X, Hagemann TL, Sosunov AA, Messing A, McKhann GM, Goldman JE (2010) Alexander disease mutant GFAP compromises glutamate transport in astrocytes. J Neuropathol Exp Neurol 69:335-345.
49. van der Knaap MS, Naidu S, Breiter SN, Blaser S, Stroink H, Springer S, Begeer JC, van Coster R, Barth PG, Thomas NH, Valk J, Powers JM (2001) Alexander disease: diagnosis with MR imaging. Am J Neuroradiol 22:541-552.
50. van der Knaap MS, Salomons GS, Li R, Franzoni E, Gutiérrez-Solana LG, Smit LM, Robinson R, Ferrie CD, Cree B, Reddy A, Thomas N, Banwell B, Barkhof F, Jakobs C, Johnson A, Messing A, Brenner M (2005) Unusual variants of Alexander disease. Ann Neurol 57:327-338.
51. van der Knaap MS, Ramesh V, Schiffmann R, Blaser S, Kyllerman M, Gholkar A, Ellison DW, van der Voorn JP, van Dooren SJ, Jakobs C, Barkhof F, Salomons GS (2006) Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology 66:494-498.
52. Vargas MR, Johnson JA (2010) Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics 7:471-481.
53. Wang LQ, Colodner KJ, Feany MB(2011) Protein misfolding and oxidative stress promote glialmediated neurodegeneration in an Alexander disease model. J Neurosci 31:2868-2877.
54. Wiche G (1998) Role of plectin in cytoskeleton organization and dynamics. J Cell Sci 111: 2477-2486.
55. Wippold FJ 2nd, Perry A, Lennerz J (2006) Neuropathology for the neuroradiologist: Rosenthal fibers. Am J Neuroradiol 27:958-961.
56. Yoshida T, Sasaki M, Yoshida M, Namekawa M, Okamoto Y, Tsujino S, Sasayama H, Mizuta I, Nakagawa M (2011) Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis. J Neurol 258: 1998-2008.
57. Ziskin JL, Nishiyama A, Rubio M, Fukaya M, Bergles DE (2007) Vesicular release of glutamate from unmyelinated axons in white matter. Nat Neurosci 10:321-330.